MCID: URT010
MIFTS: 44

Ureteral Obstruction

Data Licensing
For inquiries, contact:

Aliases & Classifications for Ureteral Obstruction

MalaCards integrated aliases for Ureteral Obstruction:

Name: Ureteral Obstruction 11 53 14

External Ids:

Disease Ontology 11 DOID:5199
ICD9CM 34 593.4
SNOMED-CT 68 197807001
UMLS 71 C0029866

Summaries for Ureteral Obstruction

MalaCards based summary: Ureteral Obstruction is related to hydronephrosis and renal fibrosis. An important gene associated with Ureteral Obstruction is TGFB1 (Transforming Growth Factor Beta 1), and among its related pathways/superpathways are Disease and MIF Mediated Glucocorticoid Regulation. The drugs Tolterodine Tartrate and Iodine have been mentioned in the context of this disorder. Affiliated tissues include kidney, bone marrow and prostate, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased shRNA abundance (Z-score > 2)

Related Diseases for Ureteral Obstruction

Diseases related to Ureteral Obstruction via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 422)
# Related Disease Score Top Affiliating Genes
1 hydronephrosis 32.0 TGFB1 SLC12A1 AQP2 AGTR2
2 renal fibrosis 31.9 TGFB1 EPO ENG BMP7 AGTR1
3 obstructive nephropathy 31.8 TGFB1 AQP2 AGTR2
4 urinary tract obstruction 31.6 TGFB1 CTNNB1 BMP7 AQP2 AGTR1
5 proteasome-associated autoinflammatory syndrome 1 31.2 PTGS2 PTGS1 NOS2 IL10
6 chronic kidney disease 31.1 TGFB1 FABP1 EPO BMP7 AQP2 AGTR1
7 kidney papillary necrosis 31.0 PTGS2 PTGS1 AQP2
8 kidney disease 30.7 TGFB1 LRP2 FABP1 EPO ENG CTNNB1
9 vascular disease 30.7 TP53 TGFB1 PTGS2 PDGFA NOX4 NOS2
10 glomerulonephritis 30.7 TGFB1 NOS2 LRP2 IL10 AGTR1
11 pelvic organ prolapse 30.6 TGFB1 PTGS2 CTNNB1
12 acquired immunodeficiency syndrome 30.4 TP53 NOS2 IL10 EPO
13 glandular cystitis 30.4 TP53 PTGS2
14 constipation 30.3 PTGS2 PTGS1 NOS2 IL10
15 ureteral disease 30.3 TGFB1 CTNNB1 BMP7 AQP2 AGTR1
16 pre-eclampsia 30.3 NOS2 IL10 ENG AGTR2 AGTR1
17 esophagus adenocarcinoma 30.3 TP53 PTGS2 CTNNB1
18 prostatitis 30.2 TP53 TGFB1 PTGS2 IL10
19 nephrosclerosis 30.2 TGFB1 BMP7 AGTR1
20 adenomyosis 30.2 TP53 PTGS2 IL10 CTNNB1
21 lymphangioma 30.2 TP53 PTGS2 IL10 CTNNB1
22 cakut 30.2 BMP7 AQP2 AGTR2 AGTR1
23 cholangiocarcinoma 30.2 TP53 TGFB1 PTGS2 CTNNB1
24 renal tubular acidosis 30.1 SLC9A3 SLC12A1 AQP2
25 myelofibrosis 30.1 TP53 TGFB1 EPO ENG
26 polycystic kidney disease 30.0 LRP2 EPO ENG CTNNB1 AQP2
27 hypokalemia 30.0 SLC9A3 SLC12A1 AQP2
28 deficiency anemia 29.9 TP53 NFE2L2 IL10 EPO ENG
29 diabetes mellitus 29.0 TP53 TGFB1 SLC9A3 PTGS2 PTGS1 NOS2
30 hypertension, essential 28.8 TP53 TGFB1 SLC9A3 SLC12A1 PTGS2 PTGS1
31 fibrosis of extraocular muscles, congenital, 1 11.0
32 acute kidney failure 10.8
33 endometriosis 10.7
34 urinary tract infection 10.7
35 retroperitoneal fibrosis 10.6
36 anuria 10.6
37 nephrolithiasis, calcium oxalate 10.6
38 end stage renal disease 10.6
39 vesicoureteral reflux 10.6
40 pyelonephritis 10.5
41 aortic aneurysm 10.5
42 ureterolithiasis 10.5
43 aortic aneurysm, familial abdominal, 1 10.4
44 congenital anomalies of kidney and urinary tract 2 10.4
45 peyronie disease 10.4 TGFB1 NOS2
46 urolithiasis 10.4
47 cystitis 10.4
48 uremia 10.4
49 type 1 diabetes mellitus 19 10.4 FABP1 EPO
50 plantar fascial fibromatosis 10.4 IL10 AGTR2 AGTR1

Graphical network of the top 20 diseases related to Ureteral Obstruction:



Diseases related to Ureteral Obstruction

Symptoms & Phenotypes for Ureteral Obstruction

GenomeRNAi Phenotypes related to Ureteral Obstruction according to GeneCards Suite gene sharing:

25 (show all 41)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-1 10.31 BMP7
2 Increased shRNA abundance (Z-score > 2) GR00366-A-100 10.31 BMP7 IL10
3 Increased shRNA abundance (Z-score > 2) GR00366-A-104 10.31 PTGS1
4 Increased shRNA abundance (Z-score > 2) GR00366-A-105 10.31 PTGS1
5 Increased shRNA abundance (Z-score > 2) GR00366-A-109 10.31 BMP7
6 Increased shRNA abundance (Z-score > 2) GR00366-A-111 10.31 PTGS1
7 Increased shRNA abundance (Z-score > 2) GR00366-A-113 10.31 IL10
8 Increased shRNA abundance (Z-score > 2) GR00366-A-116 10.31 TGFB1
9 Increased shRNA abundance (Z-score > 2) GR00366-A-120 10.31 TGFB1
10 Increased shRNA abundance (Z-score > 2) GR00366-A-121 10.31 PTGS1
11 Increased shRNA abundance (Z-score > 2) GR00366-A-125 10.31 IL10
12 Increased shRNA abundance (Z-score > 2) GR00366-A-137 10.31 BMP7 PTGS1
13 Increased shRNA abundance (Z-score > 2) GR00366-A-148 10.31 PTGS1
14 Increased shRNA abundance (Z-score > 2) GR00366-A-152 10.31 IL10
15 Increased shRNA abundance (Z-score > 2) GR00366-A-161 10.31 IL10
16 Increased shRNA abundance (Z-score > 2) GR00366-A-169 10.31 PTGS1 TGFB1
17 Increased shRNA abundance (Z-score > 2) GR00366-A-177 10.31 BMP7
18 Increased shRNA abundance (Z-score > 2) GR00366-A-178 10.31 TGFB1
19 Increased shRNA abundance (Z-score > 2) GR00366-A-191 10.31 PTGS1
20 Increased shRNA abundance (Z-score > 2) GR00366-A-198 10.31 IL10 TGFB1
21 Increased shRNA abundance (Z-score > 2) GR00366-A-210 10.31 IL10
22 Increased shRNA abundance (Z-score > 2) GR00366-A-213 10.31 PTGS1
23 Increased shRNA abundance (Z-score > 2) GR00366-A-214 10.31 IL10
24 Increased shRNA abundance (Z-score > 2) GR00366-A-27 10.31 BMP7
25 Increased shRNA abundance (Z-score > 2) GR00366-A-35 10.31 TGFB1
26 Increased shRNA abundance (Z-score > 2) GR00366-A-52 10.31 BMP7 IL10
27 Increased shRNA abundance (Z-score > 2) GR00366-A-53 10.31 BMP7 IL10
28 Increased shRNA abundance (Z-score > 2) GR00366-A-65 10.31 IL10
29 Increased shRNA abundance (Z-score > 2) GR00366-A-67 10.31 IL10
30 Increased shRNA abundance (Z-score > 2) GR00366-A-68 10.31 IL10
31 Increased shRNA abundance (Z-score > 2) GR00366-A-71 10.31 TGFB1
32 Increased shRNA abundance (Z-score > 2) GR00366-A-72 10.31 BMP7
33 Increased shRNA abundance (Z-score > 2) GR00366-A-74 10.31 BMP7
34 Increased shRNA abundance (Z-score > 2) GR00366-A-77 10.31 TGFB1
35 Increased shRNA abundance (Z-score > 2) GR00366-A-78 10.31 BMP7
36 Increased shRNA abundance (Z-score > 2) GR00366-A-82 10.31 IL10
37 Increased shRNA abundance (Z-score > 2) GR00366-A-83 10.31 BMP7
38 Increased shRNA abundance (Z-score > 2) GR00366-A-85 10.31 IL10
39 Increased shRNA abundance (Z-score > 2) GR00366-A-95 10.31 BMP7
40 no effect GR00402-S-1 10.15 AGTR1 AGTR2 AQP2 BMP7 CTNNB1 ENG
41 no effect GR00402-S-2 10.15 AGTR1 AGTR2 AQP2 CTNNB1 ENG EPO

MGI Mouse Phenotypes related to Ureteral Obstruction:

45 (show all 23)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.56 AGTR1 AGTR2 AQP2 BMP7 CTNNB1 ENG
2 renal/urinary system MP:0005367 10.53 AGTR1 AGTR2 AQP2 BMP7 CTNNB1 ENG
3 nervous system MP:0003631 10.48 AGTR1 AGTR2 BMP7 CTNNB1 ENG IL10
4 growth/size/body region MP:0005378 10.48 AGTR1 AGTR2 AQP2 BMP7 CTNNB1 ENG
5 cardiovascular system MP:0005385 10.41 AGTR1 AGTR2 BMP7 CTNNB1 ENG EPO
6 muscle MP:0005369 10.37 AGTR2 CTNNB1 ENG EPO IL10 NOS2
7 digestive/alimentary MP:0005381 10.36 AGTR2 BMP7 CTNNB1 ENG IL10 LRP2
8 immune system MP:0005387 10.36 AGTR1 AGTR2 BMP7 CTNNB1 ENG EPO
9 endocrine/exocrine gland MP:0005379 10.31 AGTR2 BMP7 CTNNB1 IL10 LRP2 NFE2L2
10 behavior/neurological MP:0005386 10.31 AGTR1 AGTR2 AQP2 BMP7 CTNNB1 ENG
11 neoplasm MP:0002006 10.26 AGTR2 CTNNB1 IL10 NFE2L2 NOS2 PTGS1
12 embryo MP:0005380 10.26 BMP7 CTNNB1 ENG EPO IL10 LRP2
13 cellular MP:0005384 10.26 AGTR2 CTNNB1 EPO IL10 LRP2 NFE2L2
14 liver/biliary system MP:0005370 10.24 CTNNB1 EPO FABP1 IL10 NFE2L2 NOS2
15 respiratory system MP:0005388 10.21 BMP7 CTNNB1 ENG EPO IL10 LRP2
16 craniofacial MP:0005382 10.19 BMP7 CTNNB1 ENG IL10 LRP2 NFE2L2
17 reproductive system MP:0005389 10.17 AQP2 BMP7 CTNNB1 IL10 LRP2 NFE2L2
18 limbs/digits/tail MP:0005371 10.12 BMP7 CTNNB1 ENG IL10 LRP2 NFE2L2
19 adipose tissue MP:0005375 10.11 AGTR1 AGTR2 NFE2L2 NOS2 PTGS2 TGFB1
20 hematopoietic system MP:0005397 10.11 AGTR1 AGTR2 AQP2 BMP7 CTNNB1 ENG
21 skeleton MP:0005390 10.1 AGTR2 BMP7 CTNNB1 ENG IL10 LRP2
22 mortality/aging MP:0010768 9.91 AGTR1 AGTR2 AQP2 BMP7 CTNNB1 ENG
23 integument MP:0010771 9.47 AGTR2 AQP2 BMP7 CTNNB1 ENG IL10

Drugs & Therapeutics for Ureteral Obstruction

Drugs for Ureteral Obstruction (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 32)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Tolterodine Tartrate Phase 4 124937-52-6
2
Iodine Approved, Investigational Phase 2 7553-56-2 807
3
Triclosan Approved, Investigational Phase 2 3380-34-5 5564
4
Lidocaine Approved, Vet_approved Phase 2 137-58-6 3676
5
Mirabegron Approved Phase 2 223673-61-8 18319735 9865528
6 Calcium, Dietary Phase 2
7 Adrenergic Agonists Phase 2
8 Adrenergic beta-Agonists Phase 2
9 Adrenergic beta-3 Receptor Agonists Phase 2
10
Calcium Nutraceutical Phase 2 7440-70-2 271
11
Ibuprofen Approved 15687-27-1 3672
12
Tamsulosin Approved, Investigational 106133-20-4 129211
13
Ropivacaine Approved 84057-95-4 71273 175805
14
Nickel 7440-02-0 934
15 Cyclooxygenase Inhibitors
16 Antirheumatic Agents
17 Anti-Inflammatory Agents, Non-Steroidal
18 Analgesics, Non-Narcotic
19 Anti-Inflammatory Agents
20 Analgesics
21 Muscarinic Antagonists
22 Adrenergic Antagonists
23 Adrenergic alpha-Antagonists
24 Adrenergic alpha-1 Receptor Antagonists
25 Adrenergic Agents
26 Cholinergic Antagonists
27 Cholinergic Agents
28 Neurotransmitter Agents
29 Parasympatholytics
30
Trospium chloride 10405-02-4
31 Anesthetics
32 Anesthetics, Local

Interventional clinical trials:

(show all 30)
# Name Status NCT ID Phase Drugs
1 Efficacy and Safety of a Covered Self-expandable Dual-layered Metallic Mesh Stent (UVENTA™) in Ureteral Obstruction: Prospective, Multi-center, Open Label Study Unknown status NCT01788865 Phase 4
2 Combination Versus Monotherapy With Alpha Blocker and Anticholinergics to Relieve Urinary Stent Symptoms Completed NCT01741454 Phase 4 Tamsulosin;Tolterodine ER
3 Interest of MR Urography in the Evaluation of Functional Consequences of Urinary Tract in Children and Adults Completed NCT00301470 Phase 4
4 Comparison of the Efficacy of Silicone-covered Metallic Ureteral Stent and Double-J Stent for Malignant Ureteral Obstruction: A Prospective Randomized Controlled Trial Based on Exploratory Research Unknown status NCT01823575 Phase 2
5 Efficacy and Safety of Renalof® in the Removal of Calculi Smaller Than 10 mm Located in the Reno-Ureteral Tract Completed NCT04695951 Phase 2
6 Assessment of Bacterial Adherence and Biofilm Formation on a Triclosan Loaded Ureteral Stent: A Phase II Study Completed NCT00250406 Phase 2
7 A Randomized Control Trial Comparing Single to Multiple Application Lidocaine Analgesia Prior to Urethral Catheterization Procedures Completed NCT00142064 Phase 2
8 Study of Tolerance and Effectiveness of Ureteral Stents MEMOKATH ® 051 in the Treatment of Chronic Strictures of the Ureter Completed NCT00790686 Phase 2
9 A Double Blind Placebo Control Trial of Mirabegron for Medical Expulsive Therapy and to Manage Stent Pain for Ureteral Stones(Protocol # 01-16-20-02) Completed NCT02744430 Phase 2 Mirabegron
10 Ureteral Reimplantation for the Treatment of Extrinsic Malignant Ureteral Obstruction Unknown status NCT02160652
11 Prospective Multicenter Observational Study of Early Infancy Ureteral Reimplantation for Distal Ureteral Obstruction Unknown status NCT02419339
12 Ureteropelvic Junction Obstruction in Early Childhood: Comparison of Surgical Therapy and Surveillance in Children With Scintigraphically Prooved Obstruction. A Prospective, Randomized, Controlled Multi-Center Study Unknown status NCT00444431
13 Effectiveness of Drainage of the Kidney by Percutaneous Nephrostomy Catheter Placement Vs. Retrograde Double J Catheter Placement in Patients With Symptoms of Obstructive Kidney Disease Caused by Urolithiasis Unknown status NCT04594161
14 Long-Term Temporary Drainage of Malignant Extrinsic Ureteral Obstruction Secondary to Inoperable Pelvic or Abdominal Malignancies Using the Memokath 051 Ureteral Stent Completed NCT00166361
15 Evaluation of Ureteral Length Measurement by Computed Tomography (CT) to Actual Ureteral Length Measured by Ureteral Catheterization Completed NCT01542593
16 Urinary Biomarkers as Predictors on Renal Function in Congenital Hydronephrosis Completed NCT00568724
17 Laparoscopic Pyeloplasty: A Registry and Database Completed NCT00169650
18 Double-blind, Placebo-controlled Randomized Controlled Trial of NSAID Prior to Ureteral Stent Removal in a Pediatric Population Completed NCT02140970 Ibuprofen;Placebo
19 The RELIEF™ Ureteral Stent - Assessment of Retrograde Urinary Reflux and Distal Coil Bladder Position Recruiting NCT03266770
20 Pediatric Robotic Versus Open Pyeloplasty: A Pilot Randomized Control Study Recruiting NCT04884945
21 Primary Versus Deferred Ureteroscopy for Management of Calculus Anuria in Children: A Prospective Randomized Study Recruiting NCT04980079
22 Trospium Chloride vs Tamsulosin in Treatment of Ureteral Stent Related Symptoms: A Randomized Controlled Trial Recruiting NCT03709992 Trospium Chloride;Tamsulosin
23 Cortical Transit Time on Diuretic Renogram as an Early Marker of Significant Obstruction in Antenatally Detected Uretero-pelvic Junction Syndrome Recruiting NCT02812212
24 Boston Scientific Double-J PLUS Ureteral Stent Postmarket Patient Registry Active, not recruiting NCT04197583
25 Use of SPY Fluorescent Angiography to Reduce Ureteroenteric Stricture Rate Following Urinary Diversion Enrolling by invitation NCT05022199
26 Is it Safe to Advance a Guidewire Through a Previously Deployed Double j Stent? A Prospective, Randomized, Controlled Study Not yet recruiting NCT05265936
27 The Efficacy and Safety of Local Anesthetic Infusion With Ropivacaine for the Management of Pain After Surgical Correction of Ureteropelvic Junction Stenosis Terminated NCT00930046
28 Prospective Randomized Trial of Indwelling Double-J Ureteral Stent Versus Externalized Modified-Salle Stent for Pyeloplasty Terminated NCT02713633
29 Comparison of Dynamic Contrast Enhanced CT and Diuretic Renogram in The Evaluation of Ureteropelvic Junction Obstruction Withdrawn NCT00199472
30 The Correlation Between Renal Injury and Biomarkers in Pediatric Ureteropelvic Junction Obstruction Patients Withdrawn NCT01711996

Search NIH Clinical Center for Ureteral Obstruction

Genetic Tests for Ureteral Obstruction

Anatomical Context for Ureteral Obstruction

Organs/tissues related to Ureteral Obstruction:

MalaCards : Kidney, Bone Marrow, Prostate, Myeloid, Endothelial, Cervix, Bone

Publications for Ureteral Obstruction

Articles related to Ureteral Obstruction:

(show top 50) (show all 5540)
# Title Authors PMID Year
1
IL-18 neutralization ameliorates obstruction-induced epithelial-mesenchymal transition and renal fibrosis. 53 62
19536084 2009
2
Angiotensin II type 1 receptor blockade prevents decrease in adult stem-like cells in kidney after ureteral obstruction. 53 62
17692840 2007
3
Snail1 is involved in the renal epithelial-mesenchymal transition. 53 62
17692821 2007
4
Cyclooxygenase type 2 is increased in obstructed rat and human ureter and contributes to pelvic pressure increase after obstruction. 53 62
16820795 2006
5
Elevated plasma concentrations of transforming growth factor-beta 1 in patients with unilateral ureteral obstruction. 53 62
16315065 2005
6
Angiotensin II, via AT1 and AT2 receptors and NF-kappaB pathway, regulates the inflammatory response in unilateral ureteral obstruction. 53 62
15153562 2004
7
Osteogenic protein-1 prevents renal fibrogenesis associated with ureteral obstruction. 53 62
10894795 2000
8
A review on urinary proteins in outflow disease of the upper urinary tract. 53 62
10841920 2000
9
Increased expression of TGF-beta1 but not of its receptors contributes to human obstructive nephropathy. 53 62
10594789 1999
10
Effects of experimental ureteral obstruction on platelet-derived growth factor-A and type I procollagen expression in fetal metanephric kidneys. 53 62
7819000 1994
11
SGP-2 expression as a genetic marker of progressive cellular pathology in experimental hydronephrosis. 53 62
1895664 1991
12
Determinants of ureteral obstruction after percutaneous nephrolithotomy. 62
36239748 2022
13
Alternative polyadenylation writer CSTF2 forms a positive loop with FGF2 to promote tubular epithelial-mesenchymal transition and renal fibrosis. 62
36113752 2022
14
Pro- and anti-fibrotic effects of vascular endothelial growth factor in chronic kidney diseases. 62
35618410 2022
15
Anti-EMT and anti-fibrosis effects of protocatechuic aldehyde in renal proximal tubular cells and the unilateral ureteral obstruction animal model. 62
35758295 2022
16
Ureteral morphology and pathology during urolithiasis in cats. 62
35850013 2022
17
Relaxin inhibits renal fibrosis and the epithelial-to-mesenchymal transition via the Wnt/β-catenin signaling pathway. 62
35311469 2022
18
Baicalin protects against renal interstitial fibrosis in mice by inhibiting the TGF-β/Smad signalling pathway. 62
35938471 2022
19
Gambogenic acid alleviates kidney fibrosis via epigenetic inhibition of EZH2 to regulate Smad7-dependent mechanism. 62
35994849 2022
20
Podocytes are lost from glomeruli before completing apoptosis. 62
36049065 2022
21
Nephrostomy tube versus double J ureteral stent in patients with malignant ureteric obstruction. A systematic review and meta-analysis of comparative studies. 62
36037256 2022
22
Investigation into the effect and mechanism of dapagliflozin against renal interstitial fibrosis based on transcriptome and network pharmacology. 62
36070627 2022
23
Isoandrographolide from Andrographis paniculata ameliorates tubulointerstitial fibrosis in ureteral obstruction-induced mice, associated with negatively regulating AKT/GSK-3β/β-cat signaling pathway. 62
36067652 2022
24
C3aR contributes to unilateral ureteral obstruction-induced renal interstitial fibrosis via the activation of the NLRP3 inflammasome. 62
36041502 2022
25
The hypoxia-inducible factor-α prolyl hydroxylase inhibitor FG4592 ameliorates renal fibrosis by inducing the H3K9 demethylase JMJD1A. 62
36074918 2022
26
Endophilin A2 protects against renal fibrosis by targeting TGF-β/Smad signaling. 62
36259445 2022
27
Tetratricopeptide repeat domain 36 deficiency mitigates renal tubular injury by inhibiting TGF-β1-induced epithelial-mesenchymal transition in a mouse model of chronic kidney disease. 62
36157495 2022
28
Carvacrol preserves antioxidant status and attenuates kidney fibrosis via modulation of TGF-β1/Smad signaling and inflammation. 62
36156620 2022
29
Zhen Wu decoction represses renal fibrosis by invigorating tubular NRF2 and TFAM to fuel mitochondrial bioenergetics. 62
36257219 2022
30
The gut microbe Bacteroides fragilis ameliorates renal fibrosis in mice. 62
36241632 2022
31
Long non-coding RNA FABP5P3/miR-22 axis improves TGFβ1-induced fatty acid oxidation deregulation and fibrotic changes in proximal tubular epithelial cells of renal fibrosis. 62
36196456 2022
32
Cpd-0225 attenuates renal fibrosis via inhibiting ALK5. 62
36070847 2022
33
Dihydroartemisinin suppresses renal fibrosis in mice by inhibiting DNA-methyltransferase 1 and increasing Klotho. 62
35347248 2022
34
Fatal Aerococcus urinae Aortic Valve Endocarditis with Severe Regurgitation. 62
36251625 2022
35
Editorial Comment to Magnetic resonance imaging of in vitro urine flow in single and tandem stented ureters subject to extrinsic ureteral obstruction. 62
35855587 2022
36
Magnetic resonance imaging of in vitro urine flow in single and tandem stented ureters subject to extrinsic ureteral obstruction. 62
35649584 2022
37
A Silicone-Covered Self-Expanding Metal Stent with Anti-migration Features for Treating Malignant Ureteral Obstruction. 62
35676542 2022
38
Eplerenone ameliorates lung fibrosis in unilateral ureteral obstruction rats by inhibiting lymphangiogenesis. 62
36160894 2022
39
Comparison between Antegrade versus Retrograde Ureteral Stent Placement for Malignant Ureteral Obstruction. 62
35809804 2022
40
Transmural migration of a subcutaneous ureteral bypass into the intestine in three cats. 62
35419828 2022
41
Ureteral Obstruction Promotes Ureteral Inflammation and Fibrosis. 62
36244955 2022
42
Robotic distal ureterectomy and re-implant for obstructing metastatic melanoma - surgical considerations in the palliative setting. 62
36245204 2022
43
TNF or EGFR inhibition equally block AKI-to-CKD transition: opportunities for etanercept treatment. 62
36269313 2022
44
Using Intraoperative Portable CT Scan to Minimize Reintervention Rates in Percutaneous Nephrolithotomy: A Prospective Trial. 62
35620899 2022
45
Angiopoietin-2 inhibition attenuates kidney fibrosis by hindering chemokine C-C motif ligand 2 expression and apoptosis of endothelial cells. 62
35934136 2022
46
RIPK3-MLKL signaling activates mitochondrial CaMKII and drives intrarenal extracellular matrix production during CKD. 62
35964866 2022
47
Fibrosis imaging with multiparametric proton and sodium MRI in pig injury models. 62
36151711 2022
48
Multicenter retrospective evaluation of transmural migration of subcutaneous ureteral bypass devices within the digestive tract in cats. 62
35976072 2022
49
Acute kidney injury from presumptive intramural ureteral hemorrhage secondary to diphacinone rodenticide exposure in a dog. 62
36125393 2022
50
The TLR4 signaling pathway mediates both liver and kidney injuries in mice with hepatorenal syndrome. 62
36165507 2022

Variations for Ureteral Obstruction

Expression for Ureteral Obstruction

Search GEO for disease gene expression data for Ureteral Obstruction.

Pathways for Ureteral Obstruction

Pathways related to Ureteral Obstruction according to GeneCards Suite gene sharing:

(show all 35)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.73 TP53 TGFB1 SLC12A1 PDGFA NOX4 NOS2
2
Show member pathways
13.56 TP53 TGFB1 PTGS2 PTGS1 NOS2 IL10
3
Show member pathways
13.44 TP53 TGFB1 PDGFA IL10 EPO BMP7
4
Show member pathways
12.95 TGFB1 PTGS2 PDGFA BMP7 AGTR2 AGTR1
5 12.59 CTNNB1 IL10 PDGFA TGFB1 TP53
6
Show member pathways
12.38 TP53 PDGFA NOS2 IL10 CTNNB1 AGTR1
7
Show member pathways
12.37 TP53 TGFB1 PDGFA IL10 EPO BMP7
8
Show member pathways
12.34 TGFB1 PDGFA NOX4 CTNNB1 BMP7
9
Show member pathways
12.32 CTNNB1 NOS2 PTGS1 PTGS2
10 12.13 TGFB1 ENG CTNNB1 BMP7
11 12.02 TP53 TGFB1 PTGS2 NOS2 CTNNB1
12 11.85 TP53 TGFB1 CTNNB1
13 11.82 TP53 PTGS2 NOS2
14 11.81 TGFB1 ENG BMP7
15 11.8 TGFB1 IL10 AGTR1
16 11.77 TGFB1 PTGS2 ENG
17
Show member pathways
11.7 PTGS2 PTGS1 NOS2
18 11.67 TP53 TGFB1 NOX4
19 11.66 TP53 NFE2L2 CTNNB1
20 11.64 TGFB1 CTNNB1 BMP7
21 11.61 TP53 TGFB1 PTGS2 NOX4 NOS2
22 11.6 TP53 TGFB1 IL10 CTNNB1
23 11.59 NOS2 EPO ENG
24 11.59 TP53 TGFB1 CTNNB1 BMP7
25 11.53 BMP7 NFE2L2 PDGFA TGFB1
26 11.52 PTGS2 PTGS1 CTNNB1
27 11.39 TGFB1 PDGFA EPO
28 11.3 TP53 TGFB1 PTGS2 NOS2
29 11.22 TP53 PTGS2 NOS2
30 11.15 TGFB1 PDGFA IL10
31 11.1 TGFB1 NOX4 AGTR1
32 11.05 TP53 TGFB1 PTGS2 NOS2 IL10
33 10.82 TP53 PTGS2 NOS2 EPO
34 10.64 PTGS2 PTGS1
35
Show member pathways
10.25 PTGS2 PTGS1

GO Terms for Ureteral Obstruction

Biological processes related to Ureteral Obstruction according to GeneCards Suite gene sharing:

(show all 34)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 10.41 TP53 TGFB1 NFE2L2 ENG CTNNB1 BMP7
2 positive regulation of DNA-templated transcription GO:0045893 10.41 AGTR2 BMP7 CTNNB1 EPO IL10 NFE2L2
3 positive regulation of apoptotic process GO:0043065 10.31 TP53 TGFB1 PTGS2 CTNNB1 BMP7
4 negative regulation of apoptotic process GO:0043066 10.3 TP53 PTGS2 LRP2 IL10 FABP1 EPO
5 negative regulation of gene expression GO:0010629 10.27 CTNNB1 ENG NOS2 TGFB1 TP53
6 negative regulation of cell population proliferation GO:0008285 10.23 TP53 TGFB1 PTGS2 NOX4 IL10 CTNNB1
7 response to lipopolysaccharide GO:0032496 10.19 PTGS2 NOS2 IL10 EPO
8 aging GO:0007568 10.13 EPO IL10 NFE2L2 PTGS2 TGFB1
9 positive regulation of epithelial to mesenchymal transition GO:0010718 10.12 BMP7 CTNNB1 TGFB1
10 response to hypoxia GO:0001666 10.11 TGFB1 PDGFA NOS2 EPO ENG
11 kidney development GO:0001822 10.08 LRP2 CTNNB1 BMP7 AGTR1
12 stem cell proliferation GO:0072089 10.06 TP53 TGFB1 CTNNB1
13 negative regulation of cell cycle GO:0045786 10.06 TGFB1 PTGS2 BMP7
14 cellular response to hypoxia GO:0071456 10.06 TP53 PTGS2 NFE2L2 FABP1 BMP7
15 inflammatory response GO:0006954 10.06 AGTR1 AGTR2 NFE2L2 NOS2 NOX4 PTGS1
16 positive regulation of pathway-restricted SMAD protein phosphorylation GO:0010862 10.04 BMP7 ENG TGFB1
17 positive regulation of miRNA transcription GO:1902895 10.04 IL10 TGFB1 TP53
18 positive regulation of reactive oxygen species metabolic process GO:2000379 10.04 TP53 NFE2L2 AGTR1
19 heart development GO:0007507 10.03 TP53 TGFB1 LRP2 ENG CTNNB1
20 cell population proliferation GO:0008283 10.02 TP53 TGFB1 LRP2 CTNNB1 BMP7
21 epithelial to mesenchymal transition GO:0001837 9.97 BMP7 CTNNB1 ENG TGFB1
22 positive regulation of protein kinase B signaling GO:0051897 9.97 TGFB1 PDGFA NOX4 LRP2 ENG
23 response to estradiol GO:0032355 9.96 TGFB1 PTGS2 PDGFA CTNNB1 BMP7
24 regulation of removal of superoxide radicals GO:2000121 9.93 NFE2L2 BMP7
25 positive regulation of transcription from RNA polymerase II promoter in response to stress GO:0036003 9.91 TP53 NFE2L2
26 positive regulation of transcription from RNA polymerase II promoter in response to hypoxia GO:0061419 9.9 TP53 NFE2L2
27 prostaglandin secretion GO:0032310 9.89 PTGS2 NOS2
28 response to vitamin D GO:0033280 9.89 TGFB1 PTGS2 BMP7
29 negative regulation of intrinsic apoptotic signaling pathway in response to osmotic stress GO:1902219 9.88 PTGS2 EPO
30 central nervous system vasculogenesis GO:0022009 9.88 CTNNB1 ENG
31 response to xenobiotic stimulus GO:0009410 9.77 TP53 TGFB1 PTGS2 PDGFA NFE2L2 IL10
32 response to organic substance GO:0010033 9.73 TGFB1 PTGS2 PDGFA IL10
33 positive regulation of miRNA maturation GO:1903800 9.62 TP53 TGFB1
34 regulation of cell population proliferation GO:0042127 9.4 TP53 TGFB1 PTGS2 PTGS1 NOS2 ENG

Molecular functions related to Ureteral Obstruction according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 heme binding GO:0020037 9.76 PTGS2 PTGS1 NOX4 NOS2
2 angiotensin type II receptor activity GO:0004945 9.26 AGTR2 AGTR1
3 prostaglandin-endoperoxide synthase activity GO:0004666 8.92 PTGS2 PTGS1

Sources for Ureteral Obstruction

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 24-Oct-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....